ArticleFrontiers in pharmacology2020
Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The Use of EQ-5D in the Middle East and North Africa Region: A Systematic Literature Review.PharmacoEconomics · 2025Pooled it
- Decision-Analytical Modelling of Medicines in the Middle East: A Systematic Review of Economic Evaluation Studies.Applied health economics and health policy · 2025Pooled it
- Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Pooled it
- Does health economics research align with the disease burden in the Middle East and North Africa region? A systematic review of economic evaluation studies on public health interventions.Global health research and policy · 2022Pooled it
- A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa.Applied health economics and health policy · 2022Pooled it
- Policy dialogue on health technology assessment in Middle East and North Africa: reporting from an HTAi initiative.International journal of technology assessment in health care · 2026Article
- Mapping the integration of artificial intelligence and digital technologies in health technology assessment: a scoping review protocol of global knowledge and practices.Systematic reviews · 2026Article
- Economic evaluation of cyclin-dependent kinases 4 and 6 inhibitors in advanced hormonal receptor-positive and human epidermal growth factor receptor 2 negative breast cancer: a nationwide budget impact analysis.Journal of pharmaceutical policy and practice · 2026Article
- Health system governance and pharmaceutical policy in Australia and Qatar: a comparative overview of access, reform, and equity.Journal of pharmaceutical policy and practice · 2026Article
- Beyond the Pill: Mapping Process-Oriented Decision Support Models in Pharmaceutical Policy.Healthcare (Basel, Switzerland) · 2025Review
- The global landscape of country-level health technology assessment processes: A survey among 104 countries.Health policy OPEN · 2025Article
- Challenges in adopting health technology assessment for evidence-based policy in Iran: a qualitative study.Journal of health, population, and nutrition · 2025Article
- Valuation of the EQ-5D-3L in Jordan.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Navigating barriers to health technology assessment development in Iran: a qualitative exploration of stakeholder perspectives.Archives of public health = Archives belges de sante publique · 2025Article
- Health technology assessment infrastructure for emirates health services: a phased framework.Frontiers in health services · 2025Article
- Road toward institutionalizing health technology assessment in the Emirate of Abu Dhabi: The role of evidence-informed deliberative processes.International journal of technology assessment in health care · 2024Article
- Cost-effectiveness of Procalcitonin (PCT) guidance for antibiotics management of adult sepsis patients in the Egyptian context.BMC health services research · 2024Article
- Article
- Framework for developing cost-effectiveness analysis threshold: the case of Egypt.The Journal of the Egyptian Public Health Association · 2024Article
- Preparing future doctors for evidence-based practice: a study on health technology assessment awareness and its predictors in Malaysia.International journal of technology assessment in health care · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
introductionImplementation of health technology assessment (HTA) is still in an early stage with some heterogeneity in the Middle East and North Africa (MENA). Our objective was to assess the current and future status of HTA implementation in the MENA region by focusing on regional commonalities.
methodsPreparatory discussions for the first ISPOR conference in the MENA region indicated some potentially generalizable trends of HTA roadmaps. To widen the perspective, a policy survey was conducted among conference participants by applying an HTA implementation scorecard. Discussion group members helped to validate key conclusions during and after the conference.
resultsHealth policy experts in MENA countries would like to facilitate HTA implementation and expect significant changes with some generalizable directions in 10 years compared to the current status according. HTA capacity building has to be strengthened by more graduate and postgraduate programs. Increased public budget and enhanced institutionalization are necessary success factors of HTA implementation. The scope of HTA has to be extended from pharmaceuticals to non-pharmaceutical technologies and to revision of previous policy decisions. Although cost-effectiveness with explicit threshold remains the most preferred HTA criterion, several other criteria have to be considered, maybe even by applying an explicit MCDA framework. The role of local evidence and data has to be strengthened in MENA countries, which translates to the extended use of local patient registries and payers' databases. Duplication of efforts can be reduced if international collaboration is integrated into national HTA implementation. DISCUSSION: Our results should be viewed as an initial step in a multi-stakeholder dialogue on HTA implementation. Each MENA country should develop its context-specific HTA roadmap, as such roadmaps are not transferable without taking into account country size, economic status, public health priorities and adopted systems of health care financing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.